MedTrace Logo

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.

NCT05458973 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-09-13

No results posted yet for this study

Summary

Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance or salvage therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status as well as specific resistance mechanism are unknown. Thus, the objective of this study was to prospectively collect serial blood samples in ovarian cancer patients with germline BRCA mutation who receive PARP inhibitor. We investigated circulating tumor DNA (ctDNA) before patients are started on PARP inhibitor and every 3 months thereafter until progression on PARP inhibitor. Through assessment of the changes in ctDNA mutational landscape, we aimed to investigate resistance mechanism to PARP inhibitor including BRCA reversion mutation.

Conditions

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Jung-Yun Lee · Severance hospitalYonsei University College of Medicine Department of Obstetrics and Gynecology

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05458973 on ClinicalTrials.gov